Mannucci P M
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milan, Italy.
Eur Heart J. 1995 Mar;16 Suppl A:25-30. doi: 10.1093/eurheartj/16.suppl_a.25.
A great deal of evidence suggests that fibrinogen is implicated in many vascular disorders resulting from atherothrombosis. However, it has not yet been possible either to establish with certainty whether elevated plasma fibrinogen levels cause, or arise as a consequence of, vascular pathology; or to include fibrinogen in the battery of laboratory tests widely used to predict the risk of thrombosis. This article provides an overview of the progress that has taken place in recent years in our understanding of the pathogenetic role of high plasma fibrinogen levels; the identification of genetic markers of atherothrombotic disease; and the clarification of the complex epidemiology of plasma fibrinogen levels as it relates to genotype and environment. The recent improvement in methodology used to measure plasma fibrinogen levels (which should lead to the wider use of fibrinogen assays in clinical practice) is also reviewed.
大量证据表明,纤维蛋白原与许多由动脉粥样硬化血栓形成引起的血管疾病有关。然而,目前尚无法确定血浆纤维蛋白原水平升高是导致血管病变的原因,还是血管病变的结果;也无法将纤维蛋白原纳入广泛用于预测血栓形成风险的一系列实验室检测项目中。本文概述了近年来我们在理解高血浆纤维蛋白原水平的致病作用、动脉粥样硬化血栓形成疾病遗传标记的鉴定以及阐明与基因型和环境相关的血浆纤维蛋白原水平复杂流行病学方面所取得的进展。还回顾了用于测量血浆纤维蛋白原水平的方法学的最新改进(这应会导致纤维蛋白原检测在临床实践中得到更广泛的应用)。